An ADAM17 inhibitor (TAPI2), inhibited CD44 cleavage in HNSCC cells and prevented orasphere formation (Fig. 2A and B), supporting the concept that ADAM17-mediated cleavage of CD44 regulates HNSCC cell stemness. Here, CD44 is linked to head and neck squamous cell carcinoma.